Last reviewed · How we verify
Placebo to match Jaktinib
Placebo to match Jaktinib is a Small molecule drug developed by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial).
This is a placebo formulation designed to match the appearance and administration of Jaktinib, a JAK inhibitor, for use as a control in clinical trials.
This is a placebo formulation designed to match the appearance and administration of Jaktinib, a JAK inhibitor, for use as a control in clinical trials. Used for Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial).
At a glance
| Generic name | Placebo to match Jaktinib |
|---|---|
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo-to-match formulations are inert preparations manufactured to be indistinguishable from the active drug in terms of appearance, taste, texture, and packaging. In this case, it mimics Jaktinib to maintain blinding in Phase 3 clinical trials, ensuring that neither patients nor some study personnel can identify whether they are receiving the active JAK inhibitor or placebo, thereby reducing bias in efficacy and safety assessments.
Approved indications
- Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial)
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (PHASE3)
- Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match Jaktinib CI brief — competitive landscape report
- Placebo to match Jaktinib updates RSS · CI watch RSS
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd portfolio CI